世界の平滑筋肉腫治療市場 – 2030 年までの業界動向と予測

平滑筋肉腫治療市場の分析と規模

軟部肉腫の罹患率の増加が平滑筋肉腫治療の世界市場を牽引する要因の 1 つであるため、世界の平滑筋肉腫治療市場は著しい成長を遂げています。たとえば、米国では、軟部肉腫と診断された新規症例の総数は 13,460 件で、このタイプの癌で死亡すると予想されている人は 5,350 人です。子宮筋腫を持つ女性人口の増加は LMS を発症する可能性があり、1,000 人の女性のうち 5 人に 1 人がこの癌に罹患しており、これが世界の平滑筋肉腫治療市場の成長の牽引役となっています。LMS の化学療法と放射線療法に関連する副作用は、世界の平滑筋肉腫治療市場の成長を妨げる可能性があります。たとえば、皮膚の問題、疲労、胃の不快感、特に男性人口の性的問題、口渇、貧血、脱毛、その他多くの副作用があります。                     

データブリッジマーケットリサーチは、2022年に5億8,412万米ドルだった世界の平滑筋肉腫治療市場は、2030年までに8億3,412万米ドルに達し、2023年から2030年の予測期間中に4.30％のCAGRで成長すると予測しています。発生率の上昇により、「低悪性度」が世界の平滑筋肉腫治療市場の悪性度セグメントを支配しています。データブリッジマーケットリサーチがまとめた市場レポートには、市場価値、成長率、セグメンテーション、地理的範囲、主要プレーヤーなどの市場シナリオに関する洞察に加えて、詳細な専門家の分析、患者の疫学、パイプライン分析、価格分析、規制の枠組みも含まれています。

平滑筋肉腫治療市場の範囲とセグメンテーション

市場の定義

平滑筋肉腫 (LMS) は、主に平滑筋組織に影響を及ぼす軟部肉腫の一種です。この種類の腫瘍は、胃、腸、膀胱、血管、肝臓など、体のあらゆる部分に影響を及ぼす可能性がありますが、本質的には子宮を含む腹部に影響を及ぼします。平滑筋肉腫の治療には、平滑筋肉腫の診断、治療、または管理を目的としたすべての医薬品、療法、および医療介入が含まれます。これらの製品には、化学療法、放射線療法、標的療法、免疫療法、外科的介入、および緩和ケアの選択肢が含まれます。

世界の平滑筋肉腫治療市場の動向

ドライバー

• がん研究の進歩

がん研究の分野における継続的な進歩により、平滑筋肉腫に関係する根本的なメカニズムと分子経路に関する理解が大幅に向上しました。この知識の深まりにより、より的を絞った効果的な治療オプションの開発への道が開かれました。研究者は現在、平滑筋肉腫細胞特有の特性に特に的を絞った治療法を設計し、健康な組織への害を最小限に抑え、患者の転帰を改善する可能性を秘めています。

• 発症率の上昇

Although leiomyosarcoma is considered a rare cancer, its incidence has been gradually increasing over the years. This rise can be attributed to several factors, including improved diagnostic techniques, increased awareness among healthcare providers, and potentially changing environmental factors. The growing number of leiomyosarcoma cases drives the demand for effective treatments and contributes to the expansion of the global leiomyosarcoma treatment market.

• Emerging of Treatment Modalities

Traditional treatments for leiomyosarcoma, such as surgery, chemotherapy, and radiation therapy, have limitations and can be associated with significant side effects. However, emerging treatment modalities, including precision medicine and immunotherapy, offer promising alternatives. Precision medicine involves tailoring treatment plans to the specific genetic characteristics of a patient's tumor, potentially improving treatment outcomes and reducing adverse effects. Immunotherapy harnesses the body's immune system to target and destroy cancer cells, offering a more targeted and less toxic approach to treatment.

Opportunities

• Increase Demand of Immunotherapy

Collaboration among pharmaceutical companies, academic institutions, and healthcare organizations can accelerate research and development in the leiomyosarcoma treatment field. By pooling resources, expertise, and data, collaborative efforts can overcome the challenges associated with rare diseases, ultimately leading to the development of more effective treatments.

• Collaborative Research Efforts

The rise of telemedicine and remote monitoring technologies has transformed the way healthcare is delivered. These technologies enable healthcare providers to remotely monitor emphysema patients, assess their condition, and adjust treatment plans as needed. Telemedicine improves access to care, especially for patients in rural or underserved areas. It also enhances patient education and medication adherence, ultimately leading to better disease management and outcomes

Restraints/Challenges

• Limited Treatment Options

The, leiomyosarcoma has had few available treatment options, primarily relying on surgery, chemotherapy, and radiation therapy. The limited arsenal of treatments poses challenges, particularly for patients who do not respond well to these standard approaches. The development of additional effective treatments is crucial to addressing the diverse needs of leiomyosarcoma patients.

• Rare Disease Status

Leiomyosarcoma is classified as a rare disease, which poses unique challenges for research and development efforts. Limited patient populations make it difficult to conduct large-scale clinical trials and gather sufficient data to support the approval of new treatments. This rarity also affects the overall size and growth potential of the leiomyosarcoma treatment market, making it less attractive to pharmaceutical companies.

This global leiomyosarcoma treatment market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global leiomyosarcoma treatment market Contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Recent Development

• In January 2020, Epizyme, Inc., received the U.S. Food and Drug Administration (FDA) approval for Tazverik, a target specific drug indicated for the treatment of epithelioid sarcoma in patients of age 16 and above

Global Leiomyosarcoma Treatment Market Scope

The global leiomyosarcoma treatment market is segmented on the basis of grade, classification, diagnosis, treatment, and end-user and distribution channel. The growth amongst these segments will help you analyse meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Grade

• Low Grade
• High Grade
• Others

Classification

• Leiomyosarcoma of Soft Tissue
• Leiomyosarcoma of Cutaneous Origin
• Leiomyosarcoma of Vascular Origin
• Leiomyosarcoma in the Immunocompromised Host
• Leiomyosarcoma of Bone

Diagnosis

• Blood Test
• Ultrasound
• Computed Tomography (CT) Scan
• Magnetic Resonance Imaging (MRI) Scan

Treatment

• Surgery
• Radiotherapy
• Chemotherapy
• Doxorubicin and Ifosfamide
• Gemcitabine and Taxotere (Docetaxel)
• Dacarbazine and Ecteinascidin

End-User

• Cancer Research Institutes
• Diagnostic Laboratories
• Hospitals
• Others

Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Others

Global Leiomyosarcoma Treatment Market Regional Analysis/Insights

The global leiomyosarcoma treatment market is analysed and market size insights and trends are provided by country, grade, classification, diagnosis, treatment, end-user and distribution channel as referenced above.

The countries covered in the global leiomyosarcoma treatment market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America

North America dominates the global leiomyosarcoma treatment market in terms of market share and market revenue and will continue to flourish its dominance during the forecast period. This is because of the increase in the expenditure for research and development proficiencies, increasing government’s initiatives and improved health care infrastructure in various countries.

Asia-Pacific on the other hand is projected to exhibit the highest growth rate in the global leiomyosarcoma treatment market during the forecast period of 2023 to 2030 owing to the increasing government expenditure on healthcare sector and rising technological advancements and initiatives by the government.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Global Leiomyosarcoma Treatment Market Share Analysis

The global leiomyosarcoma treatment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global leiomyosarcoma treatment market.

Some of the major players operating in the global leiomyosarcoma treatment market are:

• GSK plc. (U.S.)
• F. Hoffmann-La Roche Ltd (Switzerland)
• Novartis AG (Switzerland)
• Astrazeneca (U.S.)
• Pfizer Inc. (U.S.)
• Bristol-Myers Squibb Company (U.S.)
• Sanofi (U.S.)
• Amgen Inc. (U.S.)
• Daiichi Sankyo Company Limited (Japan)
• AB Sciences (France)
• Eisai Co., Ltd (Japan)
• Genentech Inc. (U.S)
• Merck & Co., Inc. (U.S.)

SKU-60050